Neogenomics posts smaller loss

FORT MYERS — Neogenomics, a cancer-testing laboratory, reported a smaller net loss in the second quarter as revenues grew 23% compared with the same quarter in 2010.

Neogenomics reported a net loss of $293,000 in the second quarter ending June 30, smaller than the $978,000 the company lost in the second quarter of 2010. Net revenues jumped 23% to $10.5 million because of increased number of cancer tests its employees performed.

“Driven by the addition of a number of new clients, we posted the largest increase in quarterly revenue in our corporate history,” said Neogenomics Chairman and CEO Doug VanOort, in a statement. “Importantly, we saw steady increases in the average number of tests reported per day in each month of the quarter, which allowed us to overcome historical seasonality trends.”